Lead-in: The "Purity Battle" of Targeted Therapies
In the R&D landscape of innovative and high-end generic drugs, API (Active Pharmaceutical Ingredient) quality control remains the decisive factor between success and failure. As NMPA and FDA requirements for genotoxic impurities and nitrosamine impurities (NDSRI) grow increasingly stringent, the challenge for pharmaceutical companies has shifted from "making the drug" to "precisely controlling every impurity." In this process, impurity research has become a formidable technical barrier standing in the way of every enterprise.
As a professional supplier deeply rooted in the impurity reference standard field, Sinco focuses this issue on key projects in oncology-targeted and immunomodulatory areas, covering Osimertinib, Vazegepant, Glumetinib, Etrasimod, and Upadacitinib, providing full sets of compliant analytical certificates to offer traceable reference support for your impurity studies.
Spotlight Products
EGFR-Targeted: Osimertinib Impurities
【Common Challenges】 The aminopyrimidine scaffold exhibits high reactivity, resulting in complex process-related and degradation impurity profiles. Particular attention must be paid to sulfonate ester (e.g., mesylate) genotoxic impurities.
【Sinco Offers】 A cumulative coverage of 113 related impurities, with full sets of authoritative analytical certificates (including COA, NMR, MS, HPLC, etc.), providing reference standard support for genotoxic impurity method development and risk control.
CGRP-Targeted: Vazegepant Impurities
【Common Challenges】 A small-molecule CGRP receptor antagonist containing multiple chiral centers, with a long synthetic route that makes separation of process impurities and stereoisomers highly challenging. Additionally, the molecule contains secondary/tertiary amine moieties, posing an N-nitrosamine (NDSRI) impurity risk that requires close monitoring.
【Sinco Offers】 Coverage of 8 key structures, with full analytical certificates available, providing reference standard support for complex impurity profiling and NDSRI compliance studies.
MET Inhibition: Glumetinib Impurities
【Common Challenges】 The pyrazolopyridine sulfone scaffold involves a lengthy synthetic route, resulting in a complex impurity profile of intermediates and by-products.
【Sinco Offers】 Coverage of 12 key impurities, with full structural elucidation certificates available, supporting method development and validation.
S1P Receptor Modulation: Etrasimod Impurities
【Common Challenges】 High lipophilicity leads to multiple oxidative degradation pathways. The tertiary amine structure is prone to forming N-nitroso-etrasimod (NDSRI) during manufacturing—a potential human carcinogen under strict control per FDA and ICH M7 guidelines.
【Sinco Offers】 Coverage of 67 related impurities, with full compliant analytical certificates available, supporting NDSRI impurity reference standard research and analytical method development.
JAK Pathway Inhibition: Upadacitinib Impurities
【Common Challenges】 The pyrimidinamine core generates numerous process-related impurities, and N-nitrosamine genotoxic impurity risks require vigilant monitoring.
【Sinco Offers】 Coverage of 104 related impurities, with full compliant analytical certificates available, safeguarding NDSRI impurity compliance research.
Why Sinco?
✅ Compliance Foundation: CQC certification + full structural elucidation certificates, ensuring a complete and traceable data chain.
✅ Independent Synthesis: 30,000+ self-developed library, tackling custom synthesis of high-difficulty impurities.
✅ Efficient Delivery: 24-hour response, 2–4 business days delivery for in-stock items, trusted by customers in 40 countries worldwide.
Scroll down to explore more new products.
